150 related articles for article (PubMed ID: 19142864)
1. Polymorphic loci of E2F2, CCND1 and CCND3 are associated with HER2 status of breast tumors.
Justenhoven C; Pierl CB; Haas S; Fischer HP; Hamann U; Baisch C; Harth V; Spickenheuer A; Rabstein S; Vollmert C; Illig T; Pesch B; Brüning T; Dippon J; Ko YD; Brauch H
Int J Cancer; 2009 May; 124(9):2077-81. PubMed ID: 19142864
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases.
Naidu R; Yip CH; Taib NA
Neoplasma; 2008; 55(2):87-95. PubMed ID: 18237245
[TBL] [Abstract][Full Text] [Related]
3. The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors.
Shen Q; Uray IP; Li Y; Krisko TI; Strecker TE; Kim HT; Brown PH
Oncogene; 2008 Jan; 27(3):366-77. PubMed ID: 17637753
[TBL] [Abstract][Full Text] [Related]
4. High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer.
Roy PG; Pratt N; Purdie CA; Baker L; Ashfield A; Quinlan P; Thompson AM
Int J Cancer; 2010 Jul; 127(2):355-60. PubMed ID: 19904758
[TBL] [Abstract][Full Text] [Related]
5. Expression of molecular biomarkers in primary breast tumors implanted into a surrogate host: increased levels of cyclins correlate with tumor progression.
Wani G; Noyes I; Milo GE; D'Ambrosio SM
Mol Med; 1997 Apr; 3(4):273-83. PubMed ID: 9131589
[TBL] [Abstract][Full Text] [Related]
6. HER2 Codon 655 (Ile/Val) Polymorphism and Breast Cancer in Austrian Women.
Watrowski R; Castillo-Tong DC; Wolf A; Schuster E; Fischer MB; Speiser P; Zeillinger R
Anticancer Res; 2015 Nov; 35(11):5901-4. PubMed ID: 26504013
[TBL] [Abstract][Full Text] [Related]
7. High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers.
Ahlin C; Lundgren C; Embretsén-Varro E; Jirström K; Blomqvist C; Fjällskog M-
Breast Cancer Res Treat; 2017 Aug; 164(3):667-678. PubMed ID: 28528450
[TBL] [Abstract][Full Text] [Related]
8. Association of cyclin D1 genotype with breast cancer risk and survival.
Shu XO; Moore DB; Cai Q; Cheng J; Wen W; Pierce L; Cai H; Gao YT; Zheng W
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):91-7. PubMed ID: 15668481
[TBL] [Abstract][Full Text] [Related]
9. Association of cyclin D1 A870G polymorphism with two malignancies: acute lymphoblastic leukemia and breast cancer.
Bedewy AM; Mostafa MH; Saad AA; El-Maghraby SM; Bedewy MM; Hilal AM; Kandil LS
J BUON; 2013; 18(1):227-38. PubMed ID: 23613410
[TBL] [Abstract][Full Text] [Related]
10. CCND1 and CDKN1B polymorphisms and risk of breast cancer.
Canbay E; Eraltan IY; Cercel A; Isbir T; Gazioglu E; Aydogan F; Cacina C; Cengiz A; Ferahman M; Zengin E; Unal H
Anticancer Res; 2010 Jul; 30(7):3093-8. PubMed ID: 20683061
[TBL] [Abstract][Full Text] [Related]
11. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
[TBL] [Abstract][Full Text] [Related]
12. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer and cyclin D1 gene polymorphism in Turkish women.
Yaylim-Eraltan I; Ergen A; Görmüs U; Arikan S; Küçücük S; Sahin O; Yigit N; Yildiz Y; Isbir T
In Vivo; 2009; 23(5):767-72. PubMed ID: 19779113
[TBL] [Abstract][Full Text] [Related]
14. Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cancer.
Cresti N; Lee J; Rourke E; Televantou D; Jamieson D; Verrill M; Boddy AV
Eur J Cancer; 2016 Mar; 55():27-37. PubMed ID: 26773371
[TBL] [Abstract][Full Text] [Related]
15. The CYP1B1_1358_GG genotype is associated with estrogen receptor-negative breast cancer.
Justenhoven C; Pierl CB; Haas S; Fischer HP; Baisch C; Hamann U; Harth V; Pesch B; Brüning T; Vollmert C; Illig T; Dippon J; Ko YD; Brauch H
Breast Cancer Res Treat; 2008 Sep; 111(1):171-7. PubMed ID: 17922187
[TBL] [Abstract][Full Text] [Related]
16. A positive role for PEA3 in HER2-mediated breast tumour progression.
Myers E; Hill AD; Kelly G; McDermott EW; O'Higgins NJ; Young LS
Br J Cancer; 2006 Nov; 95(10):1404-9. PubMed ID: 17060941
[TBL] [Abstract][Full Text] [Related]
17. A novel polymorphism in the promoter region of ERBB4 is associated with breast and colorectal cancer risk.
Rokavec M; Justenhoven C; Schroth W; Istrate MA; Haas S; Fischer HP; Vollmert C; Illig T; Hamann U; Ko YD; Glavac D; Brauch H
Clin Cancer Res; 2007 Dec; 13(24):7506-14. PubMed ID: 18094435
[TBL] [Abstract][Full Text] [Related]
18. CCND1 polymorphisms (A870G and C1722G) modulate its protein expression and survival in oral carcinoma.
Sathyan KM; Nalinakumari KR; Abraham T; Kannan S
Oral Oncol; 2008 Jul; 44(7):689-97. PubMed ID: 18061526
[TBL] [Abstract][Full Text] [Related]
19. The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours.
Lundberg A; Lindström LS; Li J; Harrell JC; Darai-Ramqvist E; Sifakis EG; Foukakis T; Perou CM; Czene K; Bergh J; Tobin NP
Breast Cancer Res; 2019 Feb; 21(1):34. PubMed ID: 30819233
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk.
Akisik E; Dalay N
Exp Mol Pathol; 2004 Jun; 76(3):260-3. PubMed ID: 15126109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
